Abstract 89P
Background
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy of the nasopharynx that raises public health concern in its endemic region due to its late diagnosis. The preclinical study of NPC and the bench-to-bed transition is challenged by the lack of appropriate NPC models. Conventional two-dimensional (2D) cell culture models fail to accurately replicate the complex three-dimensional (3D) structure and microenvironment of solid tumour while available 3D spheroid models for NPC do not take into account the interaction between different cell types.
Methods
In this study, we aimed to generate 3D multicellular tumour spheroids (MCTSs) to mimic the in vivo tumour architecture and microenvironment. Homotypic MCTSs were generated using Epstein-Barr virus (EBV)-positive (C666-1, NPC43) and EBV-negative NPC (HK-1) cell lines, respectively, while heterotypic MCTSs involve co-culturing EBV-positive and EBV-negative cells with stromal cells including fibroblasts (MRC-5) and HUVEC). Spheroids were constructed using the scaffold-based technique, and morphological examination was performed using light microscopy and fluorescence microscopy to characterize the spheroid size, shape and cellular organization.
Results
Homotypic and heterotypic MCTSs generated from EBV-positive and EBV-negative cell lines form spherical aggregates. H&E staining of the MCTSs demonstrated in vivo tumour characteristics, including 3D organisation, scanted cytoplasm, irregular and enlarged nuclei, and necrotic regions. EBV+ cell lines generally formed homotypic MCTSs with more compact and spherical morphology, while homotypic MCTSs generated from EBV- cell lines are less compact and displayed alveolar-like shape. The presence of NPC cells, fibroblasts, and endothelial cells in the heterotypic MCTSs were confirmed using immunofluorescence staining.
Conclusions
Homotypic and heterotypic MCTSs were generated from both EBV- and EBV+ NPC cells. The MCTSs generated replicates the in vivo tumour features in vitro. This model would serve as a platform for the study of intercellular interactions and evaluation of potential therapeutic responses.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Malaysia Ministry of Higher Education.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract